I’ve spent 11 years in pharma commercial ops and managed markets. I’ve sat through thousands of hours of conference sessions where speakers use words like “synergy” and “streamline.” Let’s be clear: those words are placeholders for a lack of actual strategy. If I hear one more person say they are going to a conference for “great networking,” I am going to lose my mind. Networking isn’t a strategy; it’s a byproduct of having a reason to be in the room.
When you are trying to drive health system adoption, you don't need a cocktail hour. You need to understand how the internal formulary process works at the IDN (Integrated Delivery Network) level. You need to know how the P&T committee views your digital tools in evidence generation, and where your pricing sits on the HTA (Health Technology Assessment) spectrum of their internal value committee.
Here is how to choose your event based on actual outcomes, not marketing brochures.
Market Access vs. Prescriber Reach
Most field teams confuse "prescriber reach" with "market access." Prescriber reach is about convincing a physician that your drug works. Health system adoption is about convincing a system that your drug is the most cost-effective option on the formulary, or that it won't break their budget under a value-based care contract.
If you send your sales reps to a clinical congress, you get a clinical win. If you send your market access team to a clinical congress, you are wasting your budget. You need executive convening forums where the people who control the budgets and the formulary gates actually show up.
The Big Three: Where They Fit
My running spreadsheet of "who you actually meet" tells a very different story than the conference websites. If you look at the websites of these organizations, they are often buried in UI clutter—cookie banners from Cookie Law Info plugins and SCOPE summit market access track clunky registration forms that suggest they care more about site compliance than user experience. Ignore the website UX and look at the attendee lists.
AMCP (Academy of Managed Care Pharmacy)
AMCP is the gold standard for PBM and health plan conversations. If your primary roadblock is the national PBM formulary or the payer’s utilization management criteria, this is where you go. However, if your focus is deep, local, health system adoption, AMCP is sometimes too broad.
- Who you actually meet: Pharmacy directors at national plans, PBM rebate negotiators, and some specialty pharmacy executives. The "Monday" takeaway: You will leave with a better understanding of how payers are tightening step-edits and prior authorizations.
The Health Management Academy (THMA)
This is where you find the C-suite. If you are selling a high-cost specialty drug or a device that requires a massive internal shift in how a hospital system bills for care, you want to be here. THMA is less about "formulary" in the pharmacy sense and more about "strategic partnerships" in the executive sense.
- Who you actually meet: CFOs, COOs, and CEOs of the largest IDNs in the US. These people do not care about your drug's specific clinical trial p-value; they care about your budget impact analysis and your pricing stability. The "Monday" takeaway: You will walk away with an understanding of what that specific IDN is prioritizing for the next fiscal year.
Association of Cancer Care Centers (ACCC)
If you are in oncology or infusion-heavy therapy, this is non-negotiable. ACCC focuses on the operational reality of cancer centers. They are dealing with 340B issues, revenue cycle management, and the practical challenges of administering complex therapies.
- Who you actually meet: Practice administrators, nurse navigators, and oncology service line directors. The "Monday" takeaway: You will learn exactly why your drug is or isn't being used—it’s rarely just about efficacy. It’s about the burden of administration and the reimbursement lag.
Comparison Matrix: Choosing the Right Venue
Focus Area AMCP THMA ACCC Primary Stakeholder Managed Care/Payer C-Suite/IDN Execs Practice Admin/Clinical Leaders Formulary Focus Payer-level/PBM System-wide P&T Site-of-Care/Infusion Value Prop Rebates & UM Strategy Budget Impact & Affordability Workflow & OperationsPricing, Affordability, and HTA Pressure
Every health system is currently under intense HTA pressure—even if they don't call it that. They are looking at their internal data to decide if your therapy is worth the spend compared to the outcomes it delivers. When you attend these events, stop asking about "market trends."
Instead, ask: "How are you reconciling the cost of this therapy against your internal budget for this service line?"
If they can't answer, they aren't the right person to talk to. If they can answer, listen. They will tell you exactly what kind of digital tools in evidence generation they need to feel comfortable moving forward. Do they need an interactive ROI calculator that proves cost-offset in 6 months? Do they need a patient-tracking dashboard? Most of these tools are being built by third parties without input from the actual users at the IDN level. Use these events to find out what actually makes their lives easier.
The Reality of Digital Presence
I find it ironic that many of these conference websites are barely functional. When I see a site loaded with Cookie Law Info pop-ups and broken navigation, it’s a symptom of a larger problem: the organization is disconnected from the digital reality of its members.
When you are vetting a conference, check their digital engagement. Do they host webinars that allow for real Q&A? Do they have a digital resource hub that provides actual case studies, or is it just white papers from vendors? If they don't prioritize their own digital infrastructure, they aren't going to help you solve your digital health adoption challenges.
What Would I Do Differently on Monday?
The "Monday" question is the only one that matters. If you go to a conference and you don't have a specific change to your strategy on Monday morning, you failed. Here is my standard post-event audit:
Identify one "No": Did someone tell you why your drug will *never* get on their formulary? Take that "no" and map it to your internal strategy. Is it the price? Is it the coding? Is it the administration burden? Filter the noise: Did you collect 50 business cards? Great. Trash 45 of them. Focus on the 5 people who can actually move the needle on formulary access in networks. Evidence Gap: Did you hear a consistent complaint about your HTA data? If three different health systems mention that your budget impact model is "too optimistic," you need to fix that model immediately. Actionable Insight: Did you learn of a specific policy change within a major IDN that affects your product? If yes, circulate that to your field teams by noon on Monday.Final Verdict
If you are trying to solve for formulary access in networks, stop going to generic pharma summits. The return on investment for those events is basically zero unless you are just there to hand out swag. Focus on the events that put you in the room with the actual decision-makers.
Use AMCP for your payer strategy. Use THMA for your IDN C-Suite relationships. Use ACCC for your clinical service line operational success. And for heaven’s sake, stop using words like "synergy." It makes you sound like a consultant, not a partner. Start talking about budgets, workflows, and evidence. That is how you get adoption.